Physician profile
Stacey Hammer
NPI 1588756662
$780.05
in general payments reported to CMS, 2019-2025
15 companies · $50.63 in 2025
The $50.63 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $80.90 · 2021: $50.03 · 2022: $29.29 · 2023: $62.57 · 2024: $333 · 2025: $50.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $445.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $240.65 | 2024 | |
| Tris Pharma INC | $108.42 | 2019-2025 | Dyanavel Xr |
| Kaleo, INC. | $89.05 | 2019-2023 | Auvi-Q |
| Sanofi Pasteur INC. | $79.15 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $49.95 | 2024-2025 | Gardasil 9, M-M-R II, Vaxelis |
| Glaxosmithkline, LLC. | $40.89 | 2019-2024 | Bexsero, Rotarix |
| Pfizer INC. | $34.46 | 2019-2024 | |
| Sobi, INC | $27.96 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $20.95 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $17.59 | 2025 | Neffy |
| Neos Therapeutics, Lp | $16.05 | 2023 | Cotempla Xr-Odt |
| Philips North America LLC | $15.61 | 2023 | |
| Galderma Laboratories, L.P. | $13.91 | 2019 | |
| Adlon Therapeutics L.P. | $12.97 | 2020 | |
| Amneal Pharmaceuticals LLC | $12.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Hammer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.